Entera Bio (STU:5DT) Cyclically Adjusted Book per Share: €-0.07 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5DT Entera Bio Ltd STU:5DT
33 GF Score
Price €1.41
! 2 Warning Signs
View Full Analysis

What is Entera Bio Cyclically Adjusted Book per Share?

Entera Bio STU:5DT -2.08% 33 Cyclically Adjusted Book per Share is €-0.07 as of Mar. 2026. GuruFocus rates STU:5DT with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Entera Bio's adjusted book value per share for the three months ended in Mar. 2026 was €0.198. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-0.07 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-14), Entera Bio's current stock price is €1.41. Entera Bio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €-0.07. Entera Bio's Cyclically Adjusted PB Ratio of today is .


Entera Bio  (STU:5DT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Entera Bio Cyclically Adjusted Book per Share Related Terms


Entera Bio Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Entera Bio's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Cyclically Adjusted Book per Share Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.07

STU:5DT vs HRTX, OKYO, EDSA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Entera Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's Cyclically Adjusted PB Ratio falls into.


STU:5DT
33GF Score
Entera Bio Ltd STU:5DT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Entera Bio's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.198/330.2130*330.2130
=0.198

Current CPI (Mar. 2026) = 330.2130.

Entera Bio Quarterly Data

Book Value per Share CPI Adj_Book
201512 -2.063 236.525 -2.880
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 -2.094 241.432 -2.864
201706 -2.084 244.955 -2.809
201709 -2.102 246.819 -2.812
201712 -2.333 246.524 -3.125
201803 0.000 249.554 0.000
201806 -2.513 251.989 -3.293
201809 0.934 252.439 1.222
201812 0.776 251.233 1.020
201903 0.592 254.202 0.769
201906 0.481 256.143 0.620
201909 0.302 256.759 0.388
201912 0.600 256.974 0.771
202003 0.497 258.115 0.636
202006 0.352 257.797 0.451
202009 0.265 260.280 0.336
202012 0.293 260.474 0.371
202103 0.269 264.877 0.335
202106 0.743 271.696 0.903
202109 0.767 274.310 0.923
202112 0.693 278.802 0.821
202203 0.622 287.504 0.714
202206 0.567 296.311 0.632
202209 0.502 296.808 0.558
202212 0.385 296.797 0.428
202303 0.327 301.836 0.358
202306 0.264 305.109 0.286
202309 0.203 307.789 0.218
202312 0.268 306.746 0.289
202403 0.230 312.332 0.243
202406 0.218 314.175 0.229
202409 0.159 315.301 0.167
202412 0.199 315.605 0.208
202503 0.395 319.799 0.408
202506 0.329 322.561 0.337
202509 0.284 324.800 0.289
202512 0.242 324.054 0.247
202603 0.198 330.213 0.198

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-0.07 mean?
Entera Bio (STU:5DT) has a Cyclically Adjusted Book per Share of €-0.07 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Entera Bio and its competitors.
Is Entera Bio's Cyclically Adjusted Book per Share too high?
Entera Bio's current Cyclically Adjusted Book per Share is €-0.07. Overall, Entera Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Cyclically Adjusted Book per Share compare to HRTX and OKYO?
Entera Bio's Cyclically Adjusted Book per Share of €-0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Entera Bio and its competitors. Entera Bio's current Cyclically Adjusted Book per Share is €-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (STU:5DT) has a current Cyclically Adjusted Book per Share of €-0.07. The current Cyclically Adjusted Book per Share is €-0.07. Entera Bio's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Entera Bio (STU:5DT), the current Cyclically Adjusted Book per Share is €-0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges ENTX:USA
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
33GF Score

Get the complete analysis for STU:5DT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.41
Price